<div id="readability-page-1"><p>TRex Bio, Inc. announced that it has received $50 million in a round of funding on January 27, 2026.The transaction included participation from new investors Janus Henderson Investors US LLC, Balyasny Asset Management L.P., Affinity Asset Advisors, LLC, returning investors Alexandria Venture Investments, LLC, Delos Advisors Limited, Eli Lilly and Company (NYSE:LLY), Johnson &amp; Johnson Innovation - JJDC, Inc., Pfizer Venture Investments LLC, Polaris Venture Partners, Inc., SV Health Investors, LLC, Avego BioScience Capital. The company issued convertible preferred shares in the transaction.</p></div>

<p>TRex Bio, Inc. 宣布于 2026 年 1 月 27 日获得 5000 万美元的融资。本轮融资吸引了新老投资者的参与，包括 Janus Henderson Investors、Balyasny Asset Management 和礼来。公司在交易中发行了可转换优先股</p>

TRex Bio, Inc. announced that it has received $50 million in funding from a group of investors

marketscreener

2 倍做多 LLY ETF - Defiance

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

礼来

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - Vanguard

Invesco Nasdaq Biotechnology ETF

PROMETHEUS BIOSCIENCES INC

美国制药 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

TRex Bio, Inc. 宣布已从一组投资者处获得 5000 万美元的融资